Zacks Investment Research downgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a buy rating to a hold rating in a research note released on Friday.
According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “
Separately, HC Wainwright restated a buy rating and set a $8.60 price objective (up from $6.50) on shares of Capricor Therapeutics in a research note on Friday, January 26th.
Capricor Therapeutics (NASDAQ CAPR) opened at $1.88 on Friday. Capricor Therapeutics has a 12-month low of $0.63 and a 12-month high of $4.25. The stock has a market cap of $51.16, a PE ratio of -2.85 and a beta of -4.66.
Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.07. The business had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $1.00 million. During the same period last year, the business earned ($0.29) earnings per share. The company’s revenue was down 58.7% on a year-over-year basis. analysts anticipate that Capricor Therapeutics will post -0.54 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in the business. Belpointe Asset Management LLC bought a new stake in Capricor Therapeutics during the 3rd quarter valued at about $249,000. Jane Street Group LLC bought a new stake in Capricor Therapeutics during the 3rd quarter valued at about $190,000. Wells Fargo & Company MN bought a new stake in Capricor Therapeutics during the 3rd quarter valued at about $107,000. Finally, Virtu KCG Holdings LLC increased its stake in Capricor Therapeutics by 571.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 179,301 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 152,614 shares in the last quarter. Institutional investors and hedge funds own 4.05% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.thestockobserver.com/2018/02/06/zacks-investment-research-downgrades-capricor-therapeutics-capr-to-hold.html.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.